Company profile: Recursion
1.1 - Company Overview
Company description
- Provider of a machine learning-driven drug discovery platform (Recursion OS), digital chemistry tools (MatchMaker), and an on-premise supercomputer (BioHive-1) to map complex biology and rapidly advance potential therapeutics; also collaborates with Bayer, Roche & Genentech, NVIDIA, Tempus, and Enamine.
Products and services
- Recursion OS: An industrial-scale platform leveraging machine learning to map complex biology, integrate chemistry, automation, data science, and engineering, and rapidly identify and advance potential therapeutics
- BioHive-1: An on-premise supercomputer accelerating development of AI foundation models for biology and chemistry, projected to be among the world's most powerful
- MatchMaker: A computational digital chemistry product predicting ligand–protein interactions, identifying potential binding between any small molecule and any protein across the human proteome
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Recursion
Sagimet Biosciences
HQ: United States
Website
- Description: Provider of novel therapeutics targeting FASN, including Denifanstat, an oral, once-daily selective FASN inhibitor in development for MASH, acne, and certain cancers, and TVB-3567, a pipeline FASN inhibitor planned for U.S. clinical development for acne.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sagimet Biosciences company profile →
Acceleron Pharma
HQ: United States
Website
- Description: Provider of novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases; engaged in developing, manufacturing, and commercializing these products, including the ACE-011 program, a novel bone-forming program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acceleron Pharma company profile →
Nurix Therapeutics
HQ: United States
Website
- Description: Provider of small molecule therapeutics and discovery via the DELigase platform leveraging E3 ligases and DNA-encoded libraries for targeted protein degradation (TPD) and elevation (TPE). Pipeline includes oral candidates NX-5948 (BTK degrader), NX-2127 (BTK/IKZF1/IKZF3 degrader), and NX-1607 (CBL-B inhibitor) for B-cell malignancies, solid tumors, and autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nurix Therapeutics company profile →
Endo
HQ: Ireland
Website
- Description: Provider of branded and generic pharmaceuticals for patient care, offering affordable, high-quality generics and treatments for unmet pelvic health needs; supplies products tailored to Canadian and emerging markets, and engages in public policy advocacy to enhance patient access, alongside a UK tax strategy focused on compliance and responsible planning.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endo company profile →
Antibe Therapeutics
HQ: Canada
Website
- Description: Provider of novel anti-inflammatory drugs that improve existing, proven therapies, targeting diseases characterized by inflammation, pain, and vascular dysfunction. Offers a proprietary hydrogen sulfide platform; pipeline includes Otenaproxesul for acute pain with demonstrated gastrointestinal safety and efficacy in chronic pain, ATB-352 for specialized pain, and a program for mild-to-moderate inflammatory bowel disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Antibe Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Recursion
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Recursion
2.2 - Growth funds investing in similar companies to Recursion
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Recursion
4.2 - Public trading comparable groups for Recursion
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →